Dr. An-gang YANG, an expert in immunology, is Cheung Kong Chair Professor of Medicine (Cheung Kong Scholar Program) and Chinese National Outstanding Youth Science Fund Owner (1999). He is a reserve candidate for Members of Chinese Academy of Science or Engineering and won the title of "Gold Star" in Science and Technology by General Department of Logistics, PLA. He enjoys the special government allowance provided by the State Council of China. He is now a professor and Director of the Department of Immunology, School of Preclinical Education, Fourth Military Medical University. He is also a Vice-Chairman, Medical Branch of Chinese Association for Biochemistry and Molecular Biology, a Consultative Expert of Population and Health Branch, a Major State Basic Research Development Program of China （973 program), and Vice-Chairman of Immunology Committee of PLA.
He is engaged in scientific research about immune therapy and gene therapy for cancer and virus infectious diseases. His research has been financially supported by grants from Chinese National Outstanding Youth Science Fund, from Cheung-Kong Scholars and Innovative Research Program in the University, from the National High Technology Research and Development Program of China (863 Program) Fund, and from Major Program of National Natural Science Foundation of China (NSFC).
He was awarded a Third Prize for National Technology Invention in 1999 (3rd place), a First Prize for Scientific and Technological Progress of Shaanxi Province in 1999 (4th place), a First Prize for Science and Technology of Shaanxi Province in 2005 (1st place), and a national invention patent of China in 2007. He has had 25 papers published on SCI journals, such as Nature, Nat Biotechnol, Hepatology and Cancer Res.
Major Academic Achievements:
1. His study demonstrated the principle that mammalian cells can be genetically modified to produce targeted toxins, indicating that in vivo production of targeted toxins can be achieved to locally or systematically destroy targeted tumor cells, or HIV infected cells. The papers were published in Nature and Nat Biotechnol in 1997.
2. He used a novel strategy to inactivate CXCR-4 or CCR-5 by targeting a modified chemokine to the endoplasmic reticulum to block the surface expression of newly synthesized chemokine. The genetically modified lymphocytes expressing this "intrakine" are immune to HIV infection. The papers were published in Nat Med and Proc Natl Acad Sci USA in 1997.
3. He expressed a kind of immuno-proapoptotic molecules of potent and selective antitumor activity, by combining the properties of a HER2-specific antibody with the activated proapoptotic molecule, such as caspase-3 and tBID. The papers were published in Cancer Res, J Biol Chem and J Immunol from 2003 to 2008.
4. He expressed fusion proteins, containing a single chain of the human variable fragment, scFv, against HBsAg, a truncated protamine (tP). siRNA could be specifically delivered into HBsAg-positive cells using the fusion protein, effectively inhibiting HBV gene expression and replication in vitro and in HBV transgenic mice. The papers were published in Hepatology and J Viral Hepat in 2007.
1. Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R, Qin WW, Jia LT, Yao LB, Zhang YQ, Chen SY, Yang AG. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res. 2007; 67:11830-11839.
2. Wen WH, Liu JY, Qin WJ , Zhao J, Wang T, Jia LT, Meng YL, Gao H, Xue CF, Jin BQ, Yao LB, Chen SY, Yang AG. Targeted inhibition of HBV gene expression by single chain antibody-mediated siRNA delivery. Hepatology, 2007; 46(1):84-94.
3. Yu CJ, Jia LT, Meng YL, Zhao J, Zhang Y, Qiu XC, Xu YM, Wen WH, Yao LB, Fan DM, Jin BQ, Chen SY, Yang AG. Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2. Gene Ther, 2006; 13: 313-320.
4. Xu YM, Wang LF, Jia LT, Qiu XC, Zhao J, Yu CJ, Zhang R, Zhu F, Wang CJ, Jin BQ, Chen SY, Yang AG. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol, 2004; 173: 61-67.
5. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z, Yu CJ, Peng WD, Wen WH, Wang CJ, Chen SY, Yang AG. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem, 2004; 279: 21343-21348.
6. Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH, Jin M, Ji ZL, Wen WH, Wang CJ, Chen SY, Yang AG. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res, 2003; 63: 3257-3262.
7. Yang AG, Chen SY. A new class of antigen-specific killer cells. Nat Biotechnol, 1997; 15: 46-51.
8. Yang AG, Bai X, Huang XF, Yao C, Chen SY. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA, 1997; 94: 11567-11572.
9. Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J, Cong Y, Yao C, Huang XF. Potent antitumour activity of a new class of tumour-specific killer cells. Nature, 1997; 385: 78-80.
10. Chen J, Bai X, Yang AG, Cong Y, Chen SY. Inactivation of HIV-1 chemokine coreceptor CXCR-4 by a novel intrakine strategy. Nat Med, 1997; 3: 1110-1116.
Professor and Director
Department of Immunology
School of Basic Medical Sciences
Fourth Military Medical University
17 Changle West Rd.
Xi'an, Shaanxi 710032